LA JOLLA, Calif., Jan. 5, 2012., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data from its proprietary lead program targeting microRNA-33a/b (miR-33a/b), currently in preclinical development for the treatment of atherosclerosis, will be presented at the Keystone Symposium "Nucleic Acid Therapeutics: From Base Pairs to Bedsides" held Jan. 10-15, 2012, in Santa Fe, New Mexico. In addition, information from its preclinical oncology programs will be presented at the American Association for Cancer Research's (AACR) Noncoding RNAs and Cancer workshop held Jan. 8-11, 2012, in Miami, Florida.
"We are pleased to present data about our proprietary microRNA programs in metabolic disease and oncology at the Keystone Symposium and AACR Special Conference respectively," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus Therapeutics. "Our scientists have made significant progress discovering potent and safe therapeutic oligonucleotide anti-miRs. We look forward to selecting clinical candidates this year for the advancement of multiple microRNA therapeutic programs into the clinic."
- Keystone Symposium: ARegulus scientist will present that targeting miR-33a/b is a promising therapeutic strategy for atherosclerosis and other aspects of the metabolic syndrome in an oral presentation titled "Targeting miR-33 for Atherosclerosis" at 8 a.m. MSTon January 14. miR-33a and miR-33b are found in the introns of SREBF2 and SREBF1 transcription factors, respectively, and work in concert with their host genes to regulate cholesterol and fatty acid synthesis. miR-33a/b target the cellular cholesterol efflux transporter ABCA1 as well as key regulators of fatty acid oxidation and insulin signaling, suggesting that inhibition of miR-33a/b could have therapeutic benefit in atherosclerosis and other aspects of the metabolic syndrome, including hepatosteatosis and insulin resistance. Studies in mice showed that antagonizing miR-33a enhanced reverse cholesterol transport, promoted regression of atherosclerosis by increasing ABCA1 in the liver and peripheral macrophages, and raised plasma HDL cholesterol. Importantly, these findings have now been translated to non-human primates, demonstrating that systemic delivery of an anti-miR-33a/b oligonucleotide increased hepatic expression of ABCA1, induced a sustained increase in circulating HDL cholesterol and decreased plasma triglycerides.
- AACR Special Conference: A Regulus scientist will present data demonstrating that microRNAs are dysregulated in cancer and are drivers of disease pathogenesis in an oral presentation titled "Anti-miR Therapeutics for Cancer" at 10:15 a.m. ESTon January 11. Regulus' oncology programs include targeting microRNA-21 (miR-21), which has been shown to be overexpressed in many cancer types promoting tumor progression and metastasis. Regulus data has demonstrated that miR-21 is up-regulated in patients with hepatocellular carcinoma (HCC) and, in preclinical models of HCC, treatment with anti-miR-21 reduces tumor formation resulting in significant survival benefit. Other efforts in oncology include the discovery of microRNA therapeutics for the treatment of glioblastoma multiforme (GBM), an orphan and rare disease with limited treatment options, performed in collaboration with Samsung Medical Center and ABC2, a non-profit organization dedicated to accelerating therapies for brain cancer patients.
Regulus is advancing multiple microRNA therapeutic programs to the clinic in the areas of fibrosis, HCV infection, immuno-inflammatory disease, metabolic disease, and oncology.
About microRNAs
in humans during the last decade is one of the most
exciting scientific breakthroughs in recent history.
microRNAs are small RNA molecules, typically 20 to 25
nucleotides in length, that do not encode proteins but
instead regulate gene expression. More than 700 microRNAs
have been identified in the human genome, and over
one-third of all human genes are believed to be regulated
by microRNAs. A single microRNA can regulate entire
networks of genes. As such, these molecules are considered
master regulators of the human genome. microRNAs have been
shown to play an integral role in numerous biological
processes, including the immune response, cell-cycle
control, metabolism, viral replication, stem cell
differentiation and human development. Most microRNAs are
conserved across multiple species, indicating the
evolutionary importance of these molecules as modulators of
critical biological pathways. Indeed, microRNA expression,
or function, has been shown to be significantly altered in
many disease states, including cancer, heart failure and
viral infections. Targeting microRNAs with anti-miRs,
antisense oligonucleotide inhibitors of microRNAs, or
miR-mimics, double-stranded oligonucleotides to replace
microRNA function opens potential for a novel class of
therapeutics and offers a unique approach to treating
disease by modulating entire biological pathways.
About Regulus Therapeutics, Inc.
Regulus Therapeutics is a biopharmaceutical company leading
the discovery and development of innovative medicines
targeting microRNAs. Regulus is using a mature therapeutic
platform based on technology that has been developed over
20 years and tested in more than 5,000 humans. The company
works with a broad network of academic collaborators and
leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam
Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals
(NASDAQ:ISIS). Regulus is advancing microRNA therapeutics
toward clinical development in several areas, including
fibrosis, hepatitis C, immuno-inflammatory diseases,
metabolic diseases and oncology. Regulus' intellectual
property estate contains both the fundamental and core
patents in the field and includes over 600 patents and more
than 300 pending patent applications pertaining primarily
to chemical modifications of oligonucleotides targeting
microRNAs for therapeutic applications. In April
2008, Regulus formed a major alliance with
GlaxoSmithKline to discover and develop microRNA
therapeutics for immuno-inflammatory diseases. In
February 2010, Regulus and GlaxoSmithKline
entered into a new collaboration to develop and
commercialize microRNA therapeutics targeting microRNA-122
for the treatment of hepatitis C infection. In June
2010, Regulus and sanofi-aventis entered into the
largest-to-date strategic alliance for the development of
microRNA therapeutics with an initial focus on fibrosis.
Forward-Looking Statements
This press release includes forward-looking statements
regarding the future therapeutic and commercial potential
of Regulus' business plans, technologies and
intellectual property related to microRNA therapeutics
being discovered and developed by Regulus, including
statements regarding the therapeutic potential of targeting
microRNAs for metabolic disease and oncology. Any statement
describing Regulus' goals, expectations, financial or
other projections, intentions or beliefs is a
forward-looking statement and should be considered an
at-risk statement. Such statements are subject to certain
risks and uncertainties, particularly those inherent in the
process of discovering, developing and commercializing
drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business
around such products. Such forward-looking statements also
involve assumptions that, if they never materialize or
prove correct, could cause the results to differ materially
from those expressed or implied by such forward-looking
statements. Although these forward-looking statements
reflect the good faith judgment of Regulus' management,
these statements are based only on facts and factors
currently known by Regulus. As a result, you are cautioned
not to rely on these forward-looking statements. These and
other risks concerning Regulus', Alnylam's, and
Isis' programs are described in additional detail in
Alnylam's and Isis' annual reports on Form 10-K for
the year ended December 31, 2010, and its most
recent quarterly report on Form 10-Q. Copies of these
and other documents are available from Alnylam or Isis.
SOURCE Regulus Therapeutics Inc.
CONTACT: Regulus Therapeutics, Zachary Zimmerman, Ph.D., busdev@regulusrx.com, +1-858-202-6300, or Russo Partners, David Schull, avid.schull@russopartnersllc.com, +1-212-845-4271
distribué par | Ce noodl a été diffusé par Isis Pharmaceuticals Inc. et initialement mise en ligne sur le site http://www.isispharm.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-05 16:15:28 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |